Key Stats for Moderna Stock
- Price change for Moderna stock: -7%
- $MRNA Stock Price as of Jul. 8: $74
- 52-Week High: $86
- $MRNA Stock Price Target: $48
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Moderna (MRNA) stock dropped 7% today after Morgan Stanley reiterated its “equal-weight” rating on the company. That rating essentially means the firm isn’t strongly bullish or bearish; it’s a neutral stance.
What’s interesting is that Morgan Stanley actually raised its price target on Moderna stock to $39 from $33, an 18% bump, citing higher expectations for the company’s COVID and flu vaccine sales.
So why would shares fall even as the price target went up? Sometimes the market reacts less to the number itself and more to the tone behind it.
Analyst Matthew Harrison’s note cited “cautious optimism,” language that suggests some confidence in growth but not enough conviction to upgrade the stock to a buy rating.
Morgan Stanley specifically called out vaccines and Moderna’s individualized cancer therapy, known as Intismeran, as the key factors that will drive the company’s valuation going forward.
This comes on the heels of a solid Q1 report from Moderna. The company posted revenue of $400 million for the quarter, above its guidance and up $300 million from the year before.
That growth was largely driven by international sales tied to long-term partnerships, particularly with the United Kingdom. Moderna reiterated its full-year guidance of up to 10% revenue growth for 2026.
On the product side, Moderna also picked up some real momentum recently. The company received European Union approval for mCOMBRIAX, the world’s first combination flu and COVID vaccine, marking its fourth approved product overall.
It also secured EU approval for mNEXSPIKE, its updated COVID vaccine. In the U.S., Moderna’s flu vaccine candidate has a regulatory decision date set for August 5.
The company’s oncology pipeline is also advancing. Moderna started a new late-stage trial for Intismeran in early-stage lung cancer, and management pointed to upcoming data presentations, including a five-year update on melanoma results.
See analysts’ growth forecasts and price targets for Moderna stock (It’s free) >>>
What the Market Is Telling Us About Moderna Stock
Today’s drop in Moderna stock shows that even good news, like a raised price target, isn’t always enough to move a stock higher if the underlying rating stays neutral.
Investors often care more about whether an analyst is telling them to buy, hold, or sell than they do about the specific dollar figure attached to a price target.
With a market cap of about $29.55 billion and 35 mRNA candidates currently in clinical studies, Moderna clearly has a lot of pipeline activity happening.
But Morgan Stanley’s stance suggests that turning this pipeline into consistent, predictable growth is still viewed as a work in progress rather than a sure thing.
For Moderna stock, the path forward likely depends on how well upcoming clinical trial results and vaccine approvals translate into actual revenue growth over the next year or two.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Moderna Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
